Company Overview
About Future Fields
Future Fields is a precision fermentation biotechnology company producing recombinant growth factors and proteins for the cultivated meat and cell therapy industries — using Drosophila (fruit fly) expression system to manufacture animal-free, scalable alternatives to animal serum-derived growth factors that are a major cost driver in cell-based biotech production. Founded in 2019 by Matthew Anderson-Baron and Jalene Anderson-Baron in Edmonton, Canada, Future Fields has raised approximately $11 million and targets the cultivated meat industry and cell therapy manufacturers who need cost-effective, animal-free growth factor supply.
Business Model & Competitive Advantage
Future Fields' EntoEngine platform uses genetically modified Drosophila to produce recombinant proteins (growth factors like FGF, EGF, IGF, TGF) at lower cost than mammalian cell expression systems — the Drosophila system is faster to scale, has lower infrastructure requirements, and produces proteins at commercially viable price points. For the cultivated meat industry, growth factors represent one of the largest cost components in cell culture media, and animal-free sources are preferred both for cost and for meeting "animal-free" product claims.
Competitive Landscape 2025–2026
In 2025, Future Fields competes with Mycenax Biotech, Ajinomoto, and conventional growth factor suppliers for the cell culture media market. The cultivated meat industry has faced headwinds as commercialization timelines have extended and regulatory approvals have been slower than anticipated, but cell therapy (CAR-T, stem cell therapy, gene therapy) manufacturing represents a large adjacent market for Future Fields' growth factors. The 2025 strategy focuses on growing revenue from cell therapy manufacturers who need GMP-grade recombinant proteins, continuing to reduce production costs, and positioning as the commercial-scale alternative to FBS-derived growth factors.
Recent Activity
View all →Foreign Filing filed 2026-11-19
Not All Proteins Scale Alike: The Antigen and Enzyme Bottleneck Native antigens are harvested directly from biological sources, such as human or animal tissues and whole pathogens to preserve structural conformations and post-translational modifications (PTMs). However, variable extraction yields and unpredictable donor availability introduces supply chain risks, driving manufacturers toward recombinant alternatives to ensure long-term […] The post Building a Resilient Supply Chain for Complex IVD Reagents (or Proteins) appeared first on Future Fields .
Key takeaways Introduction In Part 2 of this crop trait blog series, we examine selected herbicide tolerance (HT) traits and the enzymes that enable them. With a special focus on a familiar concern that often determines whether a trait moves forward: the question is no longer whether the trait protein is expressed in the plant, […] The post Herbicide Tolerance Traits: Overcoming Recombinant Protein Production and Purification Bottlenecks appeared first on Future Fields .
The post Resolving In-Vitro Diagnostic Supply Chain Constraints with the EntoEngine® appeared first on Future Fields .
Introduction The exponential growth of the global population has intensified the need to substantially increase agricultural production to ensure food security. At the same time, insect pests, weeds, and diseases are developing resistance to the control methods we have relied on to keep yields up and maintain crop quality. These needs, for more food that […] The post Biomanufacturing for Crop Traits Part 1: Understanding Expression Challenges for Plant-Incorporated Protectants (PIPs), Cry, Cyt, and Vip Insecticidal Proteins appeared first on Future Fields .
Key Differentiators
Emerging Innovator
Future Fields is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Zocdoc
Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati
Compare Future Fields with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Future Fields? Verify your company email to claim this profile and keep its description, products, and FAQs up to date.
Claim Future Fields Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Future Fields vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →